{"totalCount":7,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07142811","orgStudyIdInfo":{"id":"VIR-CHDV-V206"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection","officialTitle":"A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2025-08-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2030-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-19","studyFirstSubmitQcDate":"2025-08-19","studyFirstPostDateStruct":{"date":"2025-08-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-15","lastUpdatePostDateStruct":{"date":"2026-01-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection"},"conditionsModule":{"conditions":["Viral Hepatitis"],"keywords":["HDV","Hepatitis D Virus","Hepatitis","Chronic Hepatitis D Virus","Hepatitis D","Hepatitis D, Chronic","Hepatitis Delta Virus","Digestive System Diseases","Liver Diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","description":"Participants will receive treatment with tobevibart + elebsiran up to 240 weeks.","interventionNames":["Drug: Tobevibart","Drug: Elebsiran"]},{"label":"Arm 2","type":"EXPERIMENTAL","description":"Participants will receive Bulevirtide for approximately 48 weeks and switch to receive tobevibart + elebsiran for additional 192 weeks","interventionNames":["Drug: Tobevibart","Drug: Elebsiran","Drug: Bulevirtide"]}],"interventions":[{"type":"DRUG","name":"Tobevibart","description":"Tobevibart administered by subcutaneous injection","armGroupLabels":["Arm 1","Arm 2"],"otherNames":["VIR-3434"]},{"type":"DRUG","name":"Elebsiran","description":"Elebsiran administered by subcutaneous injection","armGroupLabels":["Arm 1","Arm 2"],"otherNames":["VIR-2218"]},{"type":"DRUG","name":"Bulevirtide","description":"Bulevirtide administered by subcutaneous injection","armGroupLabels":["Arm 2"],"otherNames":["Hepcludex"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48","timeFrame":"Week 48"},{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment","timeFrame":"24 Weeks after End of Treatment"},{"measure":"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48","timeFrame":"Week 48"}],"secondaryOutcomes":[{"measure":"Change from baseline in HDV RNA at Week 48","timeFrame":"Week 48"},{"measure":"Change from baseline in ALT at Week 48","timeFrame":"Week 48"},{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 96, Week 120, Week 144, Week 192 and Week 240","timeFrame":"Week 96, Week 120, Week 144, Week 192 and Week 240"},{"measure":"Change from baseline in HDV RNA at Week 96, Week 120, Week 144, Week 192 and Week 240","timeFrame":"Week 96, Week 120, Week 144, Week 192 and Week 240"},{"measure":"Change from baseline in ALT at Week 96, Week 120, Week 144, Week 192 and Week 240","timeFrame":"Week 96 to Week 120, Week 144, Week 192 and Week 240"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female ages 18 to 70 years at screening\n2. Positive HDV antibody or positive HDV RNA PCR result for at least 6 months prior to screening and HDV RNA ≥ 500 IU/mL at screening\n3. Noncirrhotic or compensated cirrhotic liver disease at screening\n4. On NRTI therapy against HBV for at least 12 weeks prior to day 1 or have HBV DNA \\< 10 IU/ml at screening, currently on locally approved NRTI therapy\n\nExclusion Criteria:\n\n1. Serum ALT ≥ 5 × ULN\n2. Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.\n3. History of significant liver disease from non-HBV or non-HDV etiology\n4. History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.\n5. History of anaphylaxis\n6. History of immune complex disease\n7. History of autoimmune disorder\n8. Current therapy or therapy within 24 weeks of screening with an immunomodulatory agent, immune checkpoint inhibitors, immunosuppressants, cytotoxic or chemotherapeutic agent, or chronic systemic corticosteroids.\n9. Any previous treatment with Bulivertide","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigative Site","city":"Brussels","zip":"1020","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Investigative Site","city":"Brussels","zip":"1070","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Investigative Site","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Investigative Site","city":"Sofia","zip":"1407","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Investigative Site","city":"Sofia","zip":"1431","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Investigative Site","city":"Stara Zagora","zip":"6003","country":"Bulgaria","geoPoint":{"lat":42.43205,"lon":25.64262}},{"facility":"Investigative Site","city":"Clichy","zip":"92110","country":"France","geoPoint":{"lat":48.90018,"lon":2.30952}},{"facility":"Investigative Site","city":"Créteil","zip":"94000","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Investigative Site","city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Investigative Site","city":"Rennes","zip":"35000","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Investigative Site","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Investigative Site","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Investigative Site","city":"Chisinau","zip":"2025","country":"Moldova","geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Investigative Site","city":"Amsterdam","zip":"1081 HV","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Investigative Site","city":"Nijmegen","zip":"6525 GA","country":"Netherlands","geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Investigative Site","city":"Rotterdam","zip":"3015 GD","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Investigative Site","city":"Karachi","zip":"74800","country":"Pakistan","geoPoint":{"lat":24.8608,"lon":67.0104}},{"facility":"Investigative Site","city":"Karachi","zip":"75600","country":"Pakistan","geoPoint":{"lat":24.8608,"lon":67.0104}},{"facility":"Investigative Site","city":"Lahore","zip":"54800","country":"Pakistan","geoPoint":{"lat":31.558,"lon":74.35071}},{"facility":"Investigative Site","city":"Rawalpindi","zip":"46000","country":"Pakistan","geoPoint":{"lat":33.59733,"lon":73.0479}},{"facility":"Investigative Site","city":"Bucharest","zip":"021105","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Bucharest","zip":"030303","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Investigative Site","city":"Madrid","zip":"28064","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Investigative","city":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Investigative Site","city":"Kyiv","zip":"01135","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Investigative Site","city":"London","zip":"E1 1BB","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"Manchester","zip":"M8 5RB","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Investigative Site","city":"Nottingham","zip":"NG7 2UH","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006505","term":"Hepatitis"},{"id":"D003699","term":"Hepatitis D"},{"id":"D019701","term":"Hepatitis D, Chronic"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008107","term":"Liver Diseases"}],"ancestors":[{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000718249","term":"bulevirtide"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07128550","orgStudyIdInfo":{"id":"VIR-CHDV-V205"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","officialTitle":"A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","startDateStruct":{"date":"2025-07-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2031-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-13","studyFirstSubmitQcDate":"2025-08-13","studyFirstPostDateStruct":{"date":"2025-08-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-23","lastUpdatePostDateStruct":{"date":"2026-01-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide"},"conditionsModule":{"conditions":["Viral Hepatitis"],"keywords":["HDV","Hepatitis D Virus","Hepatitis","Chronic Hepatitis D Virus","Hepatitis D","Hepatitis D, Chronic","Hepatitis Delta Virus","Digestive System Diseases","Liver Diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","description":"Participants will receive treatment with tobevibart + elebsiran up to 240 weeks.","interventionNames":["Drug: Tobevibart","Drug: Elebsiran"]},{"label":"Arm 2","type":"EXPERIMENTAL","description":"Participants will receive Bulevirtide for 24 weeks and switch to receive tobevibart + elebsiran for additional 216 weeks","interventionNames":["Drug: Tobevibart","Drug: Elebsiran","Drug: Bulevirtide"]}],"interventions":[{"type":"DRUG","name":"Tobevibart","description":"Tobevibart administered by subcutaneous injection","armGroupLabels":["Arm 1","Arm 2"],"otherNames":["VIR-3434"]},{"type":"DRUG","name":"Elebsiran","description":"Elebsiran administered by subcutaneous injection","armGroupLabels":["Arm 1","Arm 2"],"otherNames":["VIR-2218"]},{"type":"DRUG","name":"Bulevirtide","description":"Bulevirtide administered by subcutaneous injection","armGroupLabels":["Arm 2"],"otherNames":["Hepcludex"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24","timeFrame":"Week 24"},{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.","timeFrame":"24 Weeks after End of Treatment"}],"secondaryOutcomes":[{"measure":"Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 24, Week 48, Week 96, Week 120, Week 144, Week 192, and Week 240","timeFrame":"Week 24, Week 48, Week 96, Week 120, Week 144, Week 192, and Week 240"},{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48, Week 96, Week 120, Week 144, Week 192 and Week 240","timeFrame":"Week 48 , Week 96, Week 120, Week 144, Week 192 and Week 240"},{"measure":"Change from baseline in ALT at Week 24, Week 48, Week 96, Week 120, Week 144, Week 192, and Week 240","timeFrame":"Week 24, Week 48, Week 96, Week 120, Week 144, Week 192, and Week 240"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female ages 18 to 70 years at screening\n2. HDV RNA ≥ 500 IU/mL at screening\n3. Receiving BLV 2 mg SC QD for ≥ 24 weeks at Day 1\n4. Noncirrhotic or compensated cirrhotic liver disease at screening\n5. On NRTI therapy against HBV for at least 12 weeks prior to day 1 or have HBV DNA \\< 10 IU/ml at screening, currently on locally approved NRTI therapy\n\nExclusion Criteria:\n\n1. Serum ALT ≥ 5 × ULN\n2. Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.\n3. History of significant liver disease from non-HBV or non-HDV etiology\n4. History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.\n5. History of anaphylaxis\n6. History of immune complex disease\n7. History of autoimmune disorder\n8. Current therapy or therapy within 24 weeks of screening with an immunomodulatory agent, immune checkpoint inhibitors, immunosuppressants, cytotoxic or chemotherapeutic agent, or chronic systemic corticosteroids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Injury","role":"CONTACT","phone":"415-654-5281","email":"clinicaltrials@vir.bio"}],"locations":[{"facility":"Investigative Site","status":"RECRUITING","city":"Bobigny","zip":"93009","country":"France","geoPoint":{"lat":48.90982,"lon":2.45012}},{"facility":"Investigative Site","status":"RECRUITING","city":"Clichy","zip":"92110","country":"France","geoPoint":{"lat":48.90018,"lon":2.30952}},{"facility":"Investigative Site","status":"RECRUITING","city":"Créteil","zip":"94000","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Investigative Site","status":"RECRUITING","city":"Le Chesnay","zip":"78150","country":"France","geoPoint":{"lat":48.8222,"lon":2.12213}},{"facility":"Investigative Site","status":"RECRUITING","city":"Limoges","zip":"87000","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Investigative Site","status":"RECRUITING","city":"Lyon","zip":"69004","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Investigative Site","status":"RECRUITING","city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Investigative Site","status":"RECRUITING","city":"Pessac","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Investigative Site","status":"RECRUITING","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Investigative Site","status":"RECRUITING","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Investigative Site","status":"RECRUITING","city":"Villejuif","zip":"94804","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Investigative Site","status":"RECRUITING","city":"Berlin","zip":"13353","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Investigative Site","status":"RECRUITING","city":"Essen","zip":"45147","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Investigative Site","status":"RECRUITING","city":"Frankfurt am Main","zip":"60590","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Investigative Site","status":"RECRUITING","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Investigative Site","status":"RECRUITING","city":"Milan","zip":"20089","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Investigative Site","status":"RECRUITING","city":"Milan","zip":"20122","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Investigative Site","status":"RECRUITING","city":"Bucharest","zip":"021105","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","status":"RECRUITING","city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","status":"RECRUITING","city":"Bucharest","zip":"030303","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","status":"RECRUITING","city":"Craiova","zip":"200073","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Investigative Site","status":"RECRUITING","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Investigative Site","status":"RECRUITING","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Investigative Site","status":"RECRUITING","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Investigative Site","status":"RECRUITING","city":"Santander","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Investigative Site","status":"RECRUITING","city":"London","zip":"E1 1FR","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","status":"RECRUITING","city":"London","zip":"SE5 9NU","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","status":"RECRUITING","city":"Manchester","zip":"M8 5RB","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Investigative Site","status":"RECRUITING","city":"Nottingham","zip":"NG7 2UH","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006505","term":"Hepatitis"},{"id":"D003699","term":"Hepatitis D"},{"id":"D019701","term":"Hepatitis D, Chronic"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008107","term":"Liver Diseases"}],"ancestors":[{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000718249","term":"bulevirtide"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06903338","orgStudyIdInfo":{"id":"VIR-CHDV-V203"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection","officialTitle":"A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2025-03-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2031-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-03-24","studyFirstSubmitQcDate":"2025-03-24","studyFirstPostDateStruct":{"date":"2025-03-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-12","lastUpdatePostDateStruct":{"date":"2025-11-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment."},"conditionsModule":{"conditions":["Viral Hepatitis"],"keywords":["HDV","Hepatitis D Virus","Hepatitis","Chronic Hepatitis D Virus","Hepatitis D","Hepatitis D, Chronic","Hepatitis Delta Virus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":124,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1 (Tobevibart + Elebsiran)","type":"EXPERIMENTAL","description":"Participants will receive treatment with tobevibart + elebsiran for 240 weeks.","interventionNames":["Drug: Tobevibart","Drug: Elebsiran"]},{"label":"Arm 2 (Tobevibart + Elebsiran)","type":"EXPERIMENTAL","description":"Participants will receive tobevibart + elebsiran after an observational period for 240 weeks.","interventionNames":["Drug: Tobevibart","Drug: Elebsiran"]}],"interventions":[{"type":"DRUG","name":"Tobevibart","description":"Tobevibart administered by subcutaneous injection","armGroupLabels":["Arm 1 (Tobevibart + Elebsiran)","Arm 2 (Tobevibart + Elebsiran)"],"otherNames":["VIR-3434"]},{"type":"DRUG","name":"Elebsiran","description":"Elebsiran administered by subcutaneous injection","armGroupLabels":["Arm 1 (Tobevibart + Elebsiran)","Arm 2 (Tobevibart + Elebsiran)"],"otherNames":["VIR-2218"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2","timeFrame":"Up to 48 weeks"},{"measure":"Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12","timeFrame":"Up to 12 weeks"}],"secondaryOutcomes":[{"measure":"HDV RNA < LLOQ, TND at Week 48 for Arm 1 vs Week 12 for Arm 2","timeFrame":"Up to 48 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female ages 18 to 70 years at screening\n2. Chronic HDV infection for \\>/= 6 months\n3. On NRTI therapy against HBV for at least 12 weeks prior to day 1 or have HBV DNA \\< 20 IU/ml at screening, currently on locally approved NRTI therapy\n4. Serum ALT \\> ULN and \\< 5x ULN\n5. Non-cirrhotic or Compensated Cirrhotic Liver Disease at screening\n\nExclusion Criteria:\n\n1. Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.\n2. History of significant liver disease from non-HBV or non-HDV etiology\n3. History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.\n4. History of anaphylaxis\n5. History of immune complex disease\n6. History of autoimmune disorder\n7. History or evidence of alcohol or drug abuse within 6 months before screening or a positive drug screen at screening unless it can be explained by a prescribed medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigative Site","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Investigative Site","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Investigative Site","city":"Redwood City","state":"California","zip":"94063","country":"United States","geoPoint":{"lat":37.48522,"lon":-122.23635}},{"facility":"Investigative Site","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Investigative Site","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"Investigative Site","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Investigative Site","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Investigative Site","city":"Hillsborough","state":"New Jersey","zip":"08844","country":"United States","geoPoint":{"lat":40.4776,"lon":-74.62682}},{"facility":"Investigative Site","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Investigative Site","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Investigative Site","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Investigative Site","city":"Murray","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"Investigative Site","city":"Seattle","state":"Washington","zip":"98105","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Investigative Site","city":"Calgary","state":"Alberta","zip":"T2N 4Z6","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Investigative Site","city":"Montreal","state":"Quebec","zip":"H2L 4E9","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Investigative Site","city":"Montreal","zip":"H2X 1R9","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Investigative Site","city":"Ottawa","zip":"K1H8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Investigative Site","city":"Québec","zip":"G1V 4G2","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Investigative Site","city":"Vancouver","zip":"V6Z 2C7","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Investigative Site","city":"Tbilisi","zip":"0102","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Investigative Site","city":"Tbilisi","zip":"0114","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Investigative Site","city":"Tbilisi","zip":"0159","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Investigative Site","city":"Frankfurt","zip":"60590","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"Investigative Site","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Investigative Site","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Investigative Site","city":"Chisinau","zip":"2025","country":"Moldova","geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Investigative Site","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Investigative Site","city":"Karachi","zip":"74800","country":"Pakistan","geoPoint":{"lat":24.8608,"lon":67.0104}},{"facility":"Investigative Site","city":"Karachi","zip":"75600","country":"Pakistan","geoPoint":{"lat":24.8608,"lon":67.0104}},{"facility":"Investigative Site","city":"Lahore","zip":"54800","country":"Pakistan","geoPoint":{"lat":31.558,"lon":74.35071}},{"facility":"Investigative Site","city":"Rawalpindi","zip":"46000","country":"Pakistan","geoPoint":{"lat":33.59733,"lon":73.0479}},{"facility":"Investigative Site","city":"Bucharest","zip":"021105","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Bucharest","zip":"030303","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Kyiv","zip":"01135","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Investigative Site","city":"London","zip":"E1 1BB","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"Manchester","zip":"M8 5RB","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Investigative Site","city":"Nottingham","zip":"NG7 2UH","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006505","term":"Hepatitis"},{"id":"D003699","term":"Hepatitis D"},{"id":"D019701","term":"Hepatitis D, Chronic"}],"ancestors":[{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04856085","orgStudyIdInfo":{"id":"VIR-2218-1006"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection","officialTitle":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection","acronym":"MARCH"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-07-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-04-21","studyFirstSubmitQcDate":"2021-04-21","studyFirstPostDateStruct":{"date":"2021-04-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-17","lastUpdatePostDateStruct":{"date":"2025-10-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy"},"conditionsModule":{"conditions":["Hepatitis B, Chronic"],"keywords":["Hepatitis B Virus","Chronic Hepatitis B","HBV","Hepatitis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":244,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 2a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 3a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 4a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 5a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 6a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 7a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 8a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 1b (VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 for 44 weeks","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 2b (VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 for 20 weeks","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434","Drug: PEG-IFNα"]},{"label":"Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434","Drug: PEG-IFNα"]},{"label":"Cohort 1d (VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks","interventionNames":["Drug: VIR-3434","Drug: PEG-IFNα"]}],"interventions":[{"type":"DRUG","name":"VIR-2218","description":"VIR-2218 given by subcutaneous injection","armGroupLabels":["Cohort 1a (VIR-2218 + VIR-3434)","Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 2a (VIR-2218 + VIR-3434)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 3a (VIR-2218 + VIR-3434)","Cohort 4a (VIR-2218 + VIR-3434)","Cohort 5a (VIR-2218 + VIR-3434)","Cohort 6a (VIR-2218 + VIR-3434)","Cohort 7a (VIR-2218 + VIR-3434)","Cohort 8a (VIR-2218 + VIR-3434)"],"otherNames":["Elebsiran"]},{"type":"DRUG","name":"VIR-3434","description":"VIR-3434 given by subcutaneous injection","armGroupLabels":["Cohort 1a (VIR-2218 + VIR-3434)","Cohort 1b (VIR-3434)","Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 1d (VIR-3434 + PEG-IFNα)","Cohort 2a (VIR-2218 + VIR-3434)","Cohort 2b (VIR-3434)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 3a (VIR-2218 + VIR-3434)","Cohort 4a (VIR-2218 + VIR-3434)","Cohort 5a (VIR-2218 + VIR-3434)","Cohort 6a (VIR-2218 + VIR-3434)","Cohort 7a (VIR-2218 + VIR-3434)","Cohort 8a (VIR-2218 + VIR-3434)"],"otherNames":["Tobevibart"]},{"type":"DRUG","name":"PEG-IFNα","description":"PEG-IFNα given by subcutaneous injection","armGroupLabels":["Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 1d (VIR-3434 + PEG-IFNα)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of participants with treatment-emergent adverse events (TEAEs)","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with serious adverse events (SAEs)","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment","timeFrame":"Up to 48 weeks"},{"measure":"Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment","timeFrame":"Up to 72 weeks"}],"secondaryOutcomes":[{"measure":"Absolute serum HBsAg and change from baseline across all timepoints in the study","timeFrame":"Up to 110 weeks"},{"measure":"Nadir and maximum reduction of serum HBsAg from baseline","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)","timeFrame":"Up to 110 weeks"},{"measure":"For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint","timeFrame":"Up to 110 weeks"},{"measure":"For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion","timeFrame":"Up to 110 weeks"},{"measure":"Cmax","timeFrame":"Up to 110 weeks"},{"measure":"AUClast","timeFrame":"Up to 110 weeks"},{"measure":"t1/2","timeFrame":"Up to 110 weeks"},{"measure":"CL/F","timeFrame":"Up to 110 weeks"},{"measure":"Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation","timeFrame":"Up to 60 weeks"},{"measure":"Proportion of participants meeting criteria for NRTI retreatment","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment","timeFrame":"Up to 48 weeks"},{"measure":"Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment","description":"48 weeks treatment + 24 weeks post-end of treatment","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with anti-HBs seroconversion","timeFrame":"Up to 110 weeks"},{"measure":"Time to achieve nadir of serum HBsAg","timeFrame":"Up to 110 weeks"},{"measure":"Time to achieve serum HBsAg loss","timeFrame":"Up to 110 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ages 18 - \\<66 years\n* Chronic HBV infection for \\>/= 6 months\n* On NRTI therapy for \\>/= 2 months at the time of screening\n\nExclusion Criteria:\n\n* Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation\n* Significant fibrosis or cirrhosis\n* History or evidence of drug or alcohol abuse\n* History of chronic liver disease from any cause other than chronic HBV infection\n* History of hepatic decompensation\n* History of anaphylaxis\n* History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434\n* History of immune complex disease\n* History of known contraindication to any interferon product","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigative Site","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Investigative Site","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Investigative Site","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Investigative Site","city":"Baltimore","state":"Maryland","zip":"21218","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Investigative Site","city":"Hillsborough","state":"New Jersey","zip":"08844","country":"United States","geoPoint":{"lat":40.4776,"lon":-74.62682}},{"facility":"Investigative Site","city":"Toronto","zip":"2C4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigative Site","city":"Toronto","zip":"3M1","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigative Site","city":"Vancouver","zip":"2C7","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Investigative Site","city":"Frankfurt","zip":"60590","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"Investigative Site","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Investigative Site","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"Investigative Site","city":"Hong Kong","state":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Investigative Site","city":"Hong Kong","state":"Tai Po District","country":"Hong Kong"},{"facility":"Investigative Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Investigative Site","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Investigative Site","city":"Chisinau","zip":"MD 2025","country":"Moldova","geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Investigative Site","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Investigative Site","city":"Auckland","zip":"2025","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Investigative Site","city":"Hamilton","zip":"3204","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Investigative Site","city":"Tauranga","zip":"3110","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Investigative Site","city":"Wellington","zip":"6021","country":"New Zealand","geoPoint":{"lat":-41.28664,"lon":174.77557}},{"facility":"Investigative Site","city":"Bucharest","zip":"021105","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Busan","zip":"49421","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Investigative Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Investigative Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Investigative Site","city":"Yangsan","zip":"50612","country":"South Korea","geoPoint":{"lat":35.34199,"lon":129.03358}},{"facility":"Investigative Site","city":"Chiayi City","zip":"60041","country":"Taiwan","geoPoint":{"lat":23.47917,"lon":120.44889}},{"facility":"Investigative Site","city":"Kaohsiung City","zip":"80756","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Investigative Site","city":"Kaohsiung City","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Investigative Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Investigative Site","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Investigative Site","city":"Taoyuan","zip":"33305","country":"Taiwan","geoPoint":{"lat":24.99368,"lon":121.29696}},{"facility":"Investigative Site","city":"Kyiv","zip":"01135","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Investigative Site","city":"Birmingham","zip":"B15 2TH","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"Investigative Site","city":"London","zip":"E11FR","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"Manchester","zip":"M8 5RB","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D019694","term":"Hepatitis B, Chronic"},{"id":"D006509","term":"Hepatitis B"},{"id":"D006505","term":"Hepatitis"}],"ancestors":[{"id":"D000086982","term":"Blood-Borne Infections"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D018347","term":"Hepadnaviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06491563","orgStudyIdInfo":{"id":"BRII-179-835-002"},"organization":{"fullName":"Brii Biosciences Limited","class":"INDUSTRY"},"briefTitle":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","officialTitle":"A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-28","studyFirstSubmitQcDate":"2024-07-04","studyFirstPostDateStruct":{"date":"2024-07-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-26","lastUpdatePostDateStruct":{"date":"2024-12-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Brii Biosciences Limited","class":"INDUSTRY"},"collaborators":[{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy."},"conditionsModule":{"conditions":["For Treatment of Chronic Hepatitis B Virus Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","type":"EXPERIMENTAL","description":"Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy.","interventionNames":["Biological: BRII-179","Drug: BRII-835 (VIR-2218)","Biological: PEG-IFNα"]},{"label":"BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα","type":"EXPERIMENTAL","description":"Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy.","interventionNames":["Biological: BRII-179","Drug: BRII-835 (VIR-2218)","Biological: PEG-IFNα"]}],"interventions":[{"type":"BIOLOGICAL","name":"BRII-179","description":"BRII-179 will be given via intramuscular injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"]},{"type":"DRUG","name":"BRII-835 (VIR-2218)","description":"BRII-835 will be given via subcutaneous injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"],"otherNames":["elebsiran"]},{"type":"BIOLOGICAL","name":"PEG-IFNα","description":"PEG-IFNα will be given via subcutaneous injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"],"otherNames":["Pegylated interferon alfa"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint","timeFrame":"24 weeks post end of treatment"}],"secondaryOutcomes":[{"measure":"Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint (in participants with lower baseline HBsAg levels)","timeFrame":"24 weeks post end of treatment"},{"measure":"Percentage of participants with treatment-emergent adverse events (TEAEs)","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Percentage of participants with serious adverse events (SAEs)","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Percentage of participants with abnormalities in hematology, chemistry, and/or coagulation parameters","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Appearance of anti-HBs at any timepoint","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Titers of anti-HBs at any timepoint","timeFrame":"24 weeks post NRTI discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1\\. Male or female aged 18-60 years.\n* 2\\. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.\n* 3\\. Chronic HBV infection for ≥ 6 months.\n* 4\\. On NRTI therapy for ≥ 6 months.\n\nExclusion Criteria:\n\n* 1\\. Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.\n* 2\\. Significant liver fibrosis or cirrhosis.\n* 3\\. History or evidence of drug or alcohol abuse.\n* 4\\. History of intolerance to SC or IM injection.\n* 5\\. History of chronic liver disease from any cause other than chronic HBV infection.\n* 6\\. History of hepatic decompensation.\n* 7\\. Contraindications to the use of PEG-IFNα.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Xiaofei Chen","affiliation":"Brii Biosciences Limited","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Investigative Site 86004","city":"Beijing","state":"Beijing Municipality","zip":"100000","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Investigative Site 86009","city":"Beijing","state":"Beijing Municipality","zip":"100000","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Investigative Site 86015","city":"Xiamen","state":"Fujian","zip":"361000","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Investigative Site 86012","city":"Foshan","state":"Guangdong","zip":"528000","country":"China","geoPoint":{"lat":23.02677,"lon":113.13148}},{"facility":"Investigative Site 86001","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Investigative Site 86013","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Investigative Site 86002","city":"Shenzhen","state":"Guangdong","zip":"518000","country":"China","geoPoint":{"lat":22.54554,"lon":114.0683}},{"facility":"Investigative Site 86003","city":"Shanghai","state":"Shanghai Municipality","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Investigative Site 86008","city":"Shanghai","state":"Shanghai Municipality","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Investigative Site 86007","city":"Chengdu","state":"Sichuan","zip":"610000","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Investigative Site 86011","city":"Chengdu","state":"Sichuan","zip":"610000","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Investigative Site 86005","city":"Hangzhou","state":"Zhejiang","zip":"310000","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05484206","orgStudyIdInfo":{"id":"VIR-2218-V107"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434","officialTitle":"A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-09-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09-25","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-07-15","studyFirstSubmitQcDate":"2022-07-29","studyFirstPostDateStruct":{"date":"2022-08-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-10","lastUpdatePostDateStruct":{"date":"2025-06-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.","detailedDescription":"Participants may be enrolled in Cohorts 1, 2, 3, 4, 5, 6, 7, 8, and 9 in a non-randomized way."},"conditionsModule":{"conditions":["Hepatic Impairment","Cirrhosis"],"keywords":["siRNA","Monoclonal antibody","HDV","Compensated Cirrhosis","Decompensated Cirrhosis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":144,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first","type":"EXPERIMENTAL","description":"All participants in Cohort 1 will be receiving VIR-2218 monotherapy.","interventionNames":["Drug: VIR-2218"]},{"label":"Cohort 2: CPT-C (severe HI) participants and matched healthy participants","type":"EXPERIMENTAL","description":"This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.","interventionNames":["Drug: VIR-2218"]},{"label":"Cohort 3: CPT-A (mild HI) participants and matched healthy participants","type":"EXPERIMENTAL","description":"This cohort is optional. All participants in Cohort 3 will be receiving VIR-2218 monotherapy.","interventionNames":["Drug: VIR-2218"]},{"label":"Cohort 4: CPT-A (mild HI) participants and matched healthy participants","type":"EXPERIMENTAL","description":"All participants in Cohort 4 will be receiving VIR-3434 monotherapy.","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 5: CPT-B (moderate HI) participants and matched healthy participants","type":"EXPERIMENTAL","description":"All participants in Cohort 5 will be receiving VIR-3434 monotherapy.","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 6: CPT-C (severe HI) participants and matched healthy participants","type":"EXPERIMENTAL","description":"This arm is optional based on Cohort 5. All participants in Cohort 6 will be receiving VIR-3434 monotherapy.","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 7: CPT-A (mild HI) and matched healthy participants","type":"EXPERIMENTAL","description":"All participants in Cohort 7 will be receiving VIR-3434 and VIR-2218 combination therapy.","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 8: CPT-B (moderate HI) and matched healthy participants","type":"EXPERIMENTAL","description":"All participants in Cohort 8 will be receiving VIR-3434 and VIR-2218 combination therapy.","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 9: CPT-C (severe HI) and matched healthy participants","type":"EXPERIMENTAL","description":"This arm is optional based on Cohort 8. All participants in Cohort 9 will be receiving VIR-3434 and VIR-2218 combination therapy.","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]}],"interventions":[{"type":"DRUG","name":"VIR-2218","description":"VIR-2218 given by subcutaneous injection.","armGroupLabels":["Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first","Cohort 2: CPT-C (severe HI) participants and matched healthy participants","Cohort 3: CPT-A (mild HI) participants and matched healthy participants","Cohort 7: CPT-A (mild HI) and matched healthy participants","Cohort 8: CPT-B (moderate HI) and matched healthy participants","Cohort 9: CPT-C (severe HI) and matched healthy participants"]},{"type":"DRUG","name":"VIR-3434","description":"VIR-3434 given by subcutaneous injection.","armGroupLabels":["Cohort 4: CPT-A (mild HI) participants and matched healthy participants","Cohort 5: CPT-B (moderate HI) participants and matched healthy participants","Cohort 6: CPT-C (severe HI) participants and matched healthy participants","Cohort 7: CPT-A (mild HI) and matched healthy participants","Cohort 8: CPT-B (moderate HI) and matched healthy participants","Cohort 9: CPT-C (severe HI) and matched healthy participants"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218","timeFrame":"5 days"},{"measure":"Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218","timeFrame":"5 days"},{"measure":"Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218","timeFrame":"5 days"},{"measure":"Maximum observed Plasma concentration (Cmax) of VIR-3434","timeFrame":"18 weeks"},{"measure":"Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434","timeFrame":"18 weeks"},{"measure":"Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434","timeFrame":"18 weeks"}],"secondaryOutcomes":[{"measure":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)","timeFrame":"Up to 18 Weeks"},{"measure":"Incidence of ADA and titers of ADA to VIR-3434 at each study visit for cohorts receiving VIR-3434 therapy","timeFrame":"18 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be ≥18 to ≤70 years of age at screening\n* Must have a calculated BMI from 18.5 ≤ BMI ≤ 40 kg/m2\n* All participants must have an eGFR ≥ 60 mL/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation\n\nInclusion criteria: Healthy matched participants\n\n* Must in the opinion of the Investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations\n\nInclusion criteria: Hepatic impaired participants\n\n* Apart from hepatic insufficiency, participants must, in the opinion of the Investigator be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations\n* Participant is considered to have chronic, stable moderate, severe, mild HI (of any etiology excluding chronic HBV and HDV) and has been clinically stable per Investigator assessment for at least 1 month prior to screening\n* CPT score of 5 to 6 for mild HI at screening\n* CPT score 7-9 for moderate HI at screening\n* CPT score 10-15 severe HI at screening\n\nExclusion Criteria:\n\n* Participants with unstable cardiac function or evidence of previous myocardial infarction in the past 12 months or any clinically significant active cardiovascular disease that, in the opinion of the Investigator, could interfere with the safety of the participant\n* Any clinically significant conduction abnormality or arrhythmia (including non-sustained or sustained ventricular tachycardia as per Investigator's assessment)\n* Infection with human immunodeficiency virus (HIV), hepatitis A virus (HAV), HBV (positive HBsAg or positive hepatitis B core antibody with negative hepatitis B surface antibody), hepatitis C virus (HCV), HDV or hepatitis E virus (HEV). HCV antibody positive participants with a negative HCV RNA are eligible. HDV antibody positive participants with a negative HDV RNA are eligible\n\nExclusion criteria: Healthy matched participants\n\n* Systolic BP is outside the range of 90-160 mmHg, or diastolic BP is outside the range of 45-95 mmHg or heart rate is outside the range of 50-100 beats per minute (bpm) for female participants or 45-100 bpm for male participants at screening\n* Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medication) within 30 days prior to D1 of study participation\n\nExclusion criteria: Participants with Hepatic impairment\n\n* Not on stable dose and regimen of any medication\n* Acute or worsening chronic hepatitis\n* Participants requiring paracentesis more than once a month\n* Participants with refractory encephalopathy or significant Central Nervous System\n* History of gastric or esophageal variceal bleeding within the past 6 months\n* Participants with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement\n* Presence of hepatopulmonary or hepatorenal syndrome\n* Presence of primarily cholestatic liver diseases\n* History of or currently listed for liver transplantation","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Inland Empire Clinical Trials","status":"RECRUITING","city":"Rialto","state":"California","zip":"92377","country":"United States","contacts":[{"name":"Amanda Benavides","role":"CONTACT","phone":"909-883-2999","email":"abenavides@ieliverfoundation.com"}],"geoPoint":{"lat":34.1064,"lon":-117.37032}},{"facility":"Orange County Research Center","status":"RECRUITING","city":"Tustin","state":"California","zip":"92790","country":"United States","contacts":[{"name":"Melanie Goerlitz","role":"CONTACT","phone":"714-550-9990","email":"Melanie.goerlitz@ocresearchcenter.com"}],"geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"CenExel Research Centers of America","status":"WITHDRAWN","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Floridian Clinical Research","status":"RECRUITING","city":"Miami Lakes","state":"Florida","zip":"33016","country":"United States","contacts":[{"name":"Julio Lopez","role":"CONTACT","phone":"305-330-9977","phoneExt":"124","email":"jlopez@floridiancr.com"}],"geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Texas Liver Institute","status":"TERMINATED","city":"San Antonio","state":"Texas","zip":"78215","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D005355","term":"Fibrosis"}],"ancestors":[{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06070051","orgStudyIdInfo":{"id":"21-0200-101"},"organization":{"fullName":"Virion Therapeutics","class":"INDUSTRY"},"briefTitle":"Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy","officialTitle":"A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-09-20","studyFirstSubmitQcDate":"2023-10-05","studyFirstPostDateStruct":{"date":"2023-10-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-29","lastUpdatePostDateStruct":{"date":"2025-05-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Virion Therapeutics","class":"INDUSTRY"},"collaborators":[{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months.\n\nApproximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.\n\nGroup 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.\n\nGroup 3 will enroll approximately 8 participants randomized into Cohort 3a or Cohort 3b. Cohort 3a will receive the high dose prime VRON-0200 vaccination of vector AdC7 on Day 1, followed by doses of VIR-2218 plus VIR-3434 on Days 28, 56, 84, 112, 140 and 168, and then a booster using a high dose VRON-0200 vaccination of vector AdC6 on Day 196. Cohort 3b will receive the same high dose prime VRON-0200 vaccination of vector AdC7 followed by 6 doses of VIR-2218 plus VIR-3434 at the same timepoints as Cohort 3a, but will not receive the booster dose on Day 196.\n\nVRON-0200 vaccine doses will be administered by intramuscular (IM) injection. VIR-2218 and VIR-3434 will be administered subcutaneously.\n\nAll study participants will be followed for a total of 1 year post-prime vaccination."},"conditionsModule":{"conditions":["Chronic Hepatitis B"],"keywords":["Hep B","Chronic Hep B","HBV","Hepatitis B Virus","Chronic Hepatitis B Virus","CHB","VRON-0200","Virion","therapeutic vaccine","VIR-2218","VIR-3434","Functional cure","Hepatitis B","Chronic Hepatitis B"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":56,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 1a will receive a low dose prime vaccination of AdC7 vector on Day 1. They will receive a low dose boost vaccination of vector AdC6 on Day 91.","interventionNames":["Biological: VRON-0200-AdC6","Biological: VRON-0200-AdC7"]},{"label":"Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 1b will receive a low dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.","interventionNames":["Biological: VRON-0200-AdC6"]},{"label":"Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 2a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive a high dose boost vaccination of AdC6 vector on Day 91.","interventionNames":["Biological: VRON-0200-AdC6","Biological: VRON-0200-AdC7"]},{"label":"Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 2b will receive a high dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.","interventionNames":["Biological: VRON-0200-AdC6"]},{"label":"Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will receive a high dose boost vaccination of AdC6 vector on Day 91.","interventionNames":["Biological: VRON-0200-AdC6","Biological: VRON-0200-AdC7","Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost","type":"EXPERIMENTAL","description":"Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will not receive a boost vaccination.","interventionNames":["Biological: VRON-0200-AdC7","Drug: VIR-2218","Drug: VIR-3434"]}],"interventions":[{"type":"BIOLOGICAL","name":"VRON-0200-AdC6","description":"VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector","armGroupLabels":["Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost","Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost","Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost"]},{"type":"BIOLOGICAL","name":"VRON-0200-AdC7","description":"VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector","armGroupLabels":["Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost","Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost","Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost"]},{"type":"DRUG","name":"VIR-2218","description":"VIR-2218 given by subcutaneous injection","armGroupLabels":["Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost","Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost"],"otherNames":["elebsiran"]},{"type":"DRUG","name":"VIR-3434","description":"VIR-3434 given by subcutaneous injection","armGroupLabels":["Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost","Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost"],"otherNames":["tobevibart","BRII-877"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment Emergent Adverse Events","description":"Number and percent of participants with 1 or more treatment-emergent adverse events within 28 days after the last dose by cohort.","timeFrame":"28 days"},{"measure":"Grade 3 Adverse Events","description":"Number and percent of participants with Grade 3 or higher local and/or systemic reactions within 28 days after the last dose by cohort.","timeFrame":"28 days"},{"measure":"Clinically Significant Changes in Lab Values","description":"Number and percent of participants with clinically significant changes from pre-vaccination laboratory values within 28 days after the last dose by cohort.","timeFrame":"28 days"},{"measure":"Serious Adverse Events","description":"Number and percent of participants with serious adverse events within 6 months after the last dose by cohort.","timeFrame":"6 months"},{"measure":"Medically Attended Adverse Events","description":"Number and percent of participants with medically attended adverse events within 6 months after the last dose by cohort.","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Adverse Events","description":"Number and percentage of adverse events for all participants through Day 360.","timeFrame":"360 days"},{"measure":"T Cell Frequencies","description":"Change from baseline in vaccine-induced CD8+ T cell frequencies in the blood.","timeFrame":"360 days"}],"otherOutcomes":[{"measure":"Hepatitis B Virus DNA","description":"Quantitative changes from baseline over time in HBV DNA","timeFrame":"360 days"},{"measure":"Hepatitis B Virus Pregenomic RNA","description":"Quantitative changes from baseline over time in HBV pgRNA","timeFrame":"360 days"},{"measure":"Hepatitis B Surface Antigen","description":"Quantitative changes from baseline over time in HBsAg","timeFrame":"360 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Documented chronic HBV infection (eg, HBsAg+ ≥ 6 months with detectable HBsAg at screening)\n2. Receipt of either entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine for at least 12 months before screening with no reported antiviral resistance during this time; still on treatment at screening and expected to stay on therapy during the study period\n3. Virally suppressed for \\> 12 months (HBV DNA \\< 40 IU/mL)\n4. No clinical diagnosis of advanced liver fibrosis and/or cirrhosis\n\nExclusion Criteria:\n\n1. History of hepatic decompensation, advanced fibrosis, or liver transplantation\n2. History of hepatocellular carcinoma\n3. History of risk factors for thrombosis and thrombocytopenia\n4. Documented hepatitis A, hepatitis C, hepatitis D, hepatitis E, or HIV (or history of prior active disease)\n5. Pregnant, nursing, or planning a pregnancy during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sue Currie, PhD","affiliation":"Virion Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Chinese University of Hong Kong","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Aotearoa Clinical Trials, Middlemore Hospital","city":"Auckland","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Auckland City Hospital","city":"Auckland","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D019694","term":"Hepatitis B, Chronic"},{"id":"D006509","term":"Hepatitis B"}],"ancestors":[{"id":"D000086982","term":"Blood-Borne Infections"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D018347","term":"Hepadnaviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D006505","term":"Hepatitis"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}
]}